Iterum Therapeutics initiates two Phase 3 clinical trials for sulopenem

Iterum Therapeutics announced its initiation of the second and third of three planned Phase 3 clinical trials for sulopenem, Iterum’s lead compound and novel antibiotic for the treatment of gram-negative, multi-drug resistant infections. In the second trial, known as sulopenem for resistant enterobacteriaceae, or SURE 2, IV sulopenem followed by oral sulopenem etzadroxil combined with probenecid in a bilayer tablet will be compared to IV ertapenem followed by oral ciprofloxacin in adults with complicated urinary tract infections. In the third trial, known as SURE 3, IV sulopenem followed by oral sulopenem is compared to IV ertapenem followed by a combination of oral ciprofloxacin and oral metronidazole in adults with complicated intra-abdominal infections. Read more at: https://thefly.com/landingPageNews.php?id=2791967
https://thefly.com/landingPageNews.php?id=2791967